1186127-11-6

Basic information

• Product Name: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(triisopropylsilyl)-1,3-oxazole
• Synonyms: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(triisopropylsilyl)-1,3-oxazole
• CAS NO: 1186127-11-6
• Molecular Weight: 351.369
• Mol File: 1186127-11-6.mol

Chemical Properties

• Melting Point: <50 °C
• Boiling Point: 383.6±34.0 °C(Predicted)
• Density: 0.96±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(triisopropylsilyl)-1,3-oxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(triisopropylsilyl)-1,3-oxazole(1186127-11-6)
• EPA Substance Registry System: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(triisopropylsilyl)-1,3-oxazole(1186127-11-6)

Safety Data

• Hazardous Substances Data: 1186127-11-6(Hazardous Substances Data)

Usage

Tetramethyl-dioxaborolane group

Contains boron, carbon, and oxygen atoms in a ring structure

Triisopropylsilyl group

Contains silicon, carbon, and hydrogen atoms

Oxazole ring

A five-membered heterocyclic ring containing oxygen and nitrogen atoms
Used in organic synthesis and pharmaceutical research
Potential applications in drug discovery and development

Upstream product

• 80522-42-5 triisopropylsilyl trifluoromethanesulfonate 

Downstream Products

• 70380-73-3 2-(1,3-oxazol-5-yl)pyridine 
• 70380-74-4 3-(oxazol-5-yl)pyridine 
• 69902-42-7 6-bromo-1,4-dimethyl-9-H-carbazole 
• 1186127-17-2 1,4-dimethyl-6-(oxazol-5-yl)-9H-carbazole 
• 1097199-51-3 3-(oxazol-5-yl)benzaldehyde 
• 848608-55-9 5-(3-methoxyphenyl)-1,3-oxazole 
• 252928-81-7 3-(oxazol-5-yl)benzonitrile 
• 1011-51-4 5-(4-methoxyphenyl)-1,3-oxazole 
• 54867-73-1 2-(4-methoxyphenyl)-5-(4-methoxyphenyl)oxazole 
• 87150-13-8 4-(oxazol-5-yl)benzonitrile 
• 1186127-13-8 2-(oxazol-5-yl)benzonitrile 
• 1186127-15-0 ethyl 2-(oxazol-5-yl)benzoate 
• 179057-31-9 4-(oxazol-5-yl)benzaldehyde 
• 1186127-14-9 2-(oxazol-5-yl)benzaldehyde 

Relevant articles and documents

A Concise Total Synthesis of Breitfussin A and B

(Chemical Equation Presented). The first total synthesis of breitfussin A and B is described. The approach features two palladium-catalyzed cross-couplings installing the indole and pyrrole onto the oxazole core and selective lithiation/iodination of a common indole-oxazole fragment providing 2,4-diiodinated or 2-iodinated oxazoles as potential precursors for breitfussin A and B, respectively. An unexpected acid promoted deiodination was utilized in the synthesis of breitfussin B. Comparison of the synthetic material with previously reported spectral data of isolated breitfussin A and B verified the structure of the breitfussin framework.

SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

Substituted dihydropyrimidinones of formula 1 which are neutrophil elastase inhibitors and useful as medicaments for the treatment of, inter alia, COPD. Exemplary is

SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.

SUBSTITUTED DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

This invention relates to substituted dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.

HETEROCYCLIC COMPOUND

The present invention provides a compound or a salt thereof useful for an agent for the prophylaxis or treatment of neurodegenerative disease and the like. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.